Ruijmbeek, C. W. B.; Filomena, H.; Idrees, H.; Housley, M. P.; Pestel, J.; Keller, L.; Lai, J. K. H.; Linde, J.; Willemsen , R.; Piesker, J.et al.; Al-Hassnan, Z. N.; Almesned , A.; Dalinghaus , M.; van den Bersselaar, L. M.; van Slegtenhorst, M. A.; Tessadori, F.; Bakkers, J.; van Ham, T. J.; Stainier, D.; Verhagen , J. M. A.; Reischauer, S.: Biallelic variants in FLII cause pediatric cardiomyopathy by disrupting cardiomyocyte cell adhesion and myofibril organization. JCI INSIGHT 8 (17), e168247 (2023)
Researchers at the Max Planck Institute develop a new pharmacological approach that specifically targets receptor interactions – with implications for immune defense and blood pressure regulation
A team of researchers at the Max Planck Institute for Heart and Lung Research, led by Prof. Dr. Didier Y.R. Stainier, has been awarded a prestigious ERC Proof of Concept (PoC) grant to advance a groundbreaking RNA-based therapeutic strategy for Duchenne Muscular Dystrophy (DMD).